In this study, LY was specifically delivered to the tumor with the nanovesicles for inactivating CAFs and eliciting an antitumor immune response, which is expected to avoid the reverse effect caused by non-specific TGF-β1 inhibition. This evidence concerns the gene TGFB1 and neoplasm.